Welcome to our dedicated page for PACIFIC BIOSCIENCES OF CALIFORNIA SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PACIFIC BIOSCIENCES OF CALIFORNIA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PACIFIC BIOSCIENCES OF CALIFORNIA's regulatory disclosures and financial reporting.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Christian O. Henry reported open-market sales of company common stock. On February 17, he sold 331,793 shares at a weighted average price of $1.576 per share. On February 18, he sold an additional 140,874 shares at a weighted average price of $1.629 per share.
After these transactions, Henry directly held 2,814,374 shares following the February 17 sale and 2,673,500 shares following the February 18 sale, all as common stock. A footnote explains that the reported shares represent stock mandatorily sold to cover tax withholding obligations related to vesting restricted stock units, and that each sale price shown is a weighted average over a disclosed price range.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Michele Farmer reported two open-market sales of common stock that were mandatorily executed to cover tax withholding on vesting restricted stock units. On February 17, 2026, Farmer sold 35,215 shares at a weighted average price of $1.576 per share. On February 18, 2026, Farmer sold 14,952 shares at a weighted average price of $1.629 per share, reflecting sale price ranges disclosed in the footnotes. After these tax-related sales, Farmer directly owned 219,092 shares of PACB common stock.
An investor in PACB filed a Rule 144 notice covering the planned sale of 303,739 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on 02/17/2026 on the NASDAQ market.
The filing lists an aggregate market value of 478,692.66 for the shares to be sold and notes that 301,907,431 shares of this class were outstanding. The seller acquired these shares as restricted stock from the issuer on 02/15/2026, with no special payment terms disclosed.
A PACB shareholder filed a notice to sell 606,312 common shares under Rule 144. The planned sale through Morgan Stanley Smith Barney LLC has an aggregate market value of $955,547.71 and is targeted around 02/17/2026 on the NASDAQ exchange.
The shares were acquired as restricted stock from the issuer on 02/15/2026. The notice states that the seller does not know of any undisclosed material adverse information about PACB’s current or prospective operations. PACB had 301,907,431 shares outstanding at the time referenced.
Pacific Biosciences of California, Inc. reported mixed fourth-quarter and full-year 2025 results, combining solid revenue growth with large GAAP losses driven by restructuring and non-cash charges. Q4 2025 revenue rose to $44.6 million from $39.2 million, with full-year 2025 revenue edging up to $160.0 million from $154.0 million. Consumables were a key driver, reaching $21.6 million in Q4 and $82.0 million for 2025, while instrument revenue declined year over year on a full-year basis.
Non-GAAP gross margin improved to 40% for both Q4 and 2025, up from 31% and 33% in the prior-year periods, reflecting better underlying profitability. Yet GAAP net loss widened to $546.4 million for 2025 from $309.9 million, largely due to restructuring, impairment, amortization and the absence of a prior-year $154.4 million debt restructuring gain. Non-GAAP net loss improved to $158.8 million from $228.0 million, and year-end cash, cash equivalents and investments were $279.5 million. The company also completed the sale of short-read sequencing assets for net proceeds of about $48.1 million and highlighted collaborations and product innovations aimed at long-read sequencing growth.
Pacific Biosciences of California, Inc. reported an internal, interim reassignment of executive responsibilities. Effective January 28, 2026, Chief Operating Officer Mark Van Oene now oversees the company’s sales and customer support teams, duties that were previously handled by President and Chief Executive Officer Christian Henry.
At the same time, Mr. Henry has temporarily taken over responsibility for operations and research and development, which had been under Mr. Van Oene. Both executives keep their existing roles and core duties, and the company states there will be no changes to their titles or compensation in connection with this shift.
ARK Investment Management LLC and Catherine D. Wood report significant ownership in Pacific Biosciences of California, Inc. They disclose beneficial ownership of 37,264,228 shares of the company’s common stock, representing 12.34% of the class, based on an event date of December 31, 2025. ARK has sole voting power over 34,971,286 shares and shared voting power over 620,864 shares, while Wood has shared voting power over 35,592,150 shares. Both certify the holdings were acquired and are held in the ordinary course of business, not for changing or influencing control. ARK Innovation ETF is noted as a client with an interest exceeding 5%.
Pacific Biosciences of California, Inc. completed an asset sale to Illumina Cambridge Limited, transferring intellectual property and other assets tied to its short-read DNA sequencing and related reagent and detection technologies. The buyer paid $50.0 million in cash and assumed certain liabilities.
PacBio also received a non-exclusive license back to some of the sold intellectual property, allowing continued access to those technologies. At PacBio’s direction, the buyer will pay 4% of the net proceeds from the purchase price to former Apton Biosystems equity holders in connection with waived milestones, leaving PacBio with approximately $48.1 million in net cash proceeds from the transaction.
Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025. The company issued a press release that includes preliminary revenue estimates and a preliminary balance of cash, cash equivalents and investments as of December 31, 2025.
Portions of the press release that cover these preliminary figures and the forward-looking statements section are treated as filed under the "Other Events" section, while the broader business update and results discussion are furnished under results-of-operations disclosure rules. The company notes that its financial statements for this period are not yet finalized or audited and may change materially, and cautions readers not to place undue reliance on the preliminary information.
Pacific Biosciences (PACB) filed its quarterly report, highlighting restructuring impacts and continued losses. Q3 revenue was $38.4 million versus $40.0 million a year ago, while gross profit improved to $15.9 million. Operating loss narrowed to $38.9 million from $64.1 million as cost of revenue declined.
Year to date, the company recorded a net loss of $506.0 million, driven primarily by $359.3 million of accelerated amortization tied to discontinued short-read development and a $15.0 million IPR&D impairment. Stockholders’ equity fell to $36.1 million from $506.6 million at year-end. Cash and investments totaled $298.7 million as of September 30, including $56.5 million in cash. Operating cash outflow was $92.1 million for the nine months. Convertible notes totaled $645.2 million (net), including the 2029 and 2030 notes; contingent consideration from the Apton deal was reduced to $0. Shares outstanding were 301,907,431 as of October 31, 2025.